ArticleMolecular and cellular biology2004
Intra-S-phase checkpoint activation by direct CDK2 inhibition.
Article in Molecular and cellular biology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 60 citations in OpenAlex.
- Not only as a Cullin3 ligase adaptor, SPOP may also act as a molecular bridge.Genes & diseases · 2027Review
- Triggering Breast Cancer Apoptosis via Cyclin-Dependent Kinase Inhibition and DNA Damage by Novel Pyrimidinone and 1,2,4-Triazolo[4,3-ACS omega · 2024Article
- Non-canonical role for the ataxia-telangiectasia-Rad3 pathway in STAT3 activation in human multiple myeloma cells.Cellular oncology (Dordrecht, Netherlands) · 2023Article
- Anti-breast cancer synthetic peptides derived from the Anabas testudineus skin mucus fractions.Scientific reports · 2021Article
- Cell-cycle-dependent phosphorylation of RRM1 ensures efficient DNA replication and regulates cancer vulnerability to ATR inhibition.Oncogene · 2020Article
- Time varying causal network reconstruction of a mouse cell cycle.BMC bioinformatics · 2019Article
- Article
- NatB-mediated protein N-α-terminal acetylation is a potential therapeutic target in hepatocellular carcinoma.Oncotarget · 2017Article
- A Cyclin-Dependent Kinase Inhibitor, Dinaciclib, Impairs Homologous Recombination and Sensitizes Multiple Myeloma Cells to PARP Inhibition.Molecular cancer therapeutics · 2016Article
- Differential S-phase progression after irradiation of p53 functional versus non-functional tumour cells.Radiology and oncology · 2014Article
- Cyclin-dependent kinases regulate apoptosis of intestinal epithelial cells.Apoptosis : an international journal on programmed cell death · 2014Article
- Parvovirus-induced depletion of cyclin B1 prevents mitotic entry of infected cells.PLoS pathogens · 2014Article
- A high-throughput screen identifies miRNA inhibitors regulating lung cancer cell survival and response to paclitaxel.RNA biology · 2013Article
- Cyclin-dependent kinase inhibitor therapy for hematologic malignancies.Expert opinion on investigational drugs · 2013Review
- p53 and the PWWP domain containing effector proteins in chromatin damage repair.Cell & developmental biology · 2013Article
- CDK-associated Cullin 1 can promote cell proliferation and inhibit cisplatin-induced apoptosis in the AGS gastric cancer cell line.World journal of surgical oncology · 2013Article
- Plk1 phosphorylation of Orc2 promotes DNA replication under conditions of stress.Molecular and cellular biology · 2011Article
- The GLI genes as the molecular switch in disrupting Hedgehog signaling in colon cancer.Oncotarget · 2011Article
- Hepatitis C virus NS5B protein delays s phase progression in human hepatocyte-derived cells by relocalizing cyclin-dependent kinase 2-interacting protein (CINP).The Journal of biological chemistry · 2011Article
- Cyclin-dependent kinases (cdks) and the DNA damage response: rationale for cdk inhibitor-chemotherapy combinations as an anticancer strategy for solid tumors.Expert opinion on therapeutic targets · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To ensure proper progression through a cell cycle, checkpoints have evolved to play a surveillance role in maintaining genomic integrity. In this study, we demonstrate that loss of CDK2 activity activates an intra-S-phase checkpoint. CDK2 inhibition triggers a p53-p21 response via ATM- and ATR-dependent p53 phosphorylation at serine 15. Phosphorylation of other ATM and ATR downstream substrates, such as H2AX, NBS1, CHK1, and CHK2 is also increased. We show that during S phase when CDK2 activity is inhibited, there is an unexpected loading of the minichromosome maintenance complex onto chromatin. In addition, there is an increased number of cells with more than 4N DNA content, detected in the absence of p53, suggesting that rereplication can occur as a result of CDK2 disruption. Our findings identify an important role for CDK2 in the maintenance of genomic stability, acting via an ATM- and ATR-dependent pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.